BEDFORD, Mass.--(BUSINESS WIRE)--Jun. 12, 2018--
Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company
focused on the formulation, development and commercialization of
innovative therapies for diseases and conditions of the eye, today
announced that Antony Mattessich, President and Chief Executive Officer
of Ocular Therapeutix, will present at the 2018 JMP Securities Life
Sciences Conference on Wednesday, June 20, 2018 at 3:30 PM ET at the St.
Regis New York Hotel in New York, NY.
In addition to the presentation, the management team will host investor
meetings at the conference. Investors attending the conference who are
interested in meeting with Ocular Therapeutix management should contact
their JMP Securities representative.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the
formulation, development and commercialization of innovative therapies
for diseases and conditions of the eye using its proprietary
bioresorbable hydrogel-based formulation technology. Ocular
Therapeutix’s lead product candidate, DEXTENZA™ (dexamethasone insert),
has completed Phase 3 clinical development for the treatment of ocular
pain and inflammation following ophthalmic surgery. OTX-TP (travoprost
insert) is in Phase 3 clinical development for the reduction of
intraocular pressure in patients with primary open-angle glaucoma and
ocular hypertension. The Company’s earlier stage assets include OTX-TIC,
an extended-delivery travoprost intracameral implant for the reduction
of intraocular pressure in patients with glaucoma and ocular
hypertension, as well as sustained release intravitreal implants for the
treatment of retinal diseases. These intravitreal implants include the
development of OTX-TKI, a tyrosine kinase inhibitor (TKI), and, in
collaboration with Regeneron, OTX-IVT, an extended-delivery
protein-based anti-vascular endothelial growth factor (VEGF) trap.
Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to
seal corneal incisions following cataract surgery.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180612005122/en/
Source: Ocular Therapeutix, Inc.
Chris Brinzey, 339-970-2843
Senior Vice President, Commercial